VYNE shareholders approve 2023 Equity Incentive Plan; CEO granted 225K RSUs and options

VYNE Therapeutics Inc.

Stockholders approved 2023 Equity Incentive Plan authorizing 2,099,856 shares, effective Dec 13, 2023.
CEO David Domzalski receives 225,000 RSUs and options for 225,000 shares on Dec 13, 2023, and another 225,000 RSUs and options on Jan 1, 2024.
Each of three other named executives (Harsch, Stuart, Zeronda) gets 62,500 RSUs and 62,500 options on both Dec 13 and Jan 1.
Annual meeting results: Sharon Barbari elected director; Baker Tilly ratified as auditor for FY2023.
Equity awards vest over four years; option exercise price equals closing price on grant date.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

VYNE Therapeutics Inc. shareholders approved Ratification of appointment of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-13 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-12-13

Exact text from the filing

Proposal 2 . The stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,666,683 113,944 27,178 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

VYNE Therapeutics Inc. shareholders approved Approval of the 2023 Plan at the 2023-12-13 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-12-13

Exact text from the filing

Proposal 3 . The stockholders approved the 2023 Plan. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,650,797 204,128 7,253 945,627

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.98

VYNE Therapeutics Inc. shareholders approved Election of director Sharon Barbari at the 2023-12-13 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-12-13

Exact text from the filing

Proposal 1 . The stockholders elected the following director to the Board, to hold office until the 2026 annual meeting of stockholders or until her successor is elected. The voting results were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Sharon Barbari 9,678,059 184,119 945,627

View on SEC.gov

Browse all shareholder votes →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-125694

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.